

Kirsten Müller-Vahl

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5832605/kirsten-muller-vahl-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

152
papers

4,507
citations

36
h-index

60
g-index

173
ext. papers

5,588
ext. citations

5
avg, IF

5.78
L-index

#	Paper	IF	Citations
152	Reply: Calling for caution: Qtop that Qsentiments threaten tic research, healthcare and advocacy progress.. <i>Brain</i> , 2022 ,	11.2	0
151	Premonitory Urges Reconsidered: Urge Location Corresponds to Tic Location in Patients With Primary Tic Disorders.. <i>Journal of Movement Disorders</i> , 2022 , 15, 43-52	2.9	0
150	Lack of Association of Group A Streptococcal Infections and Onset of Tics: European Multicenter Tics in Children Study.. <i>Neurology</i> , 2022 ,	6.5	3
149	Altered performance monitoring in Tourette Syndrome: an MEG investigation.. <i>Scientific Reports</i> , 2022 , 12, 8300	4.9	
148	European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment. <i>European Child and Adolescent Psychiatry</i> , 2021 , 1	5.5	10
147	Endocannabinoid Modulation Using Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A Phase 1 Randomized, Placebo-Controlled Study. <i>Pharmacopsychiatry</i> , 2021 ,	2	4
146	Treatment failure in persistent tic disorders: an expert clinicians Qconsensus-based definition. <i>European Child and Adolescent Psychiatry</i> , 2021 , 1	5.5	2
145	Yale Global Tic Severity Scale (YGTSS): Psychometric Quality of the Gold Standard for Tic Assessment Based on the Large-Scale EMTICS Study. <i>Frontiers in Psychiatry</i> , 2021 , 12, 626459	5	5
144	European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part IV: deep brain stimulation. <i>European Child and Adolescent Psychiatry</i> , 2021 , 1	5.5	2
143	European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part I: assessment. <i>European Child and Adolescent Psychiatry</i> , 2021 , 1	5.5	3
142	Clinical Practice Patterns in Tic Disorders Among Movement Disorder Society Members. <i>Tremor and Other Hyperkinetic Movements</i> , 2021 , 11, 43	2	1
141	Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome. <i>Neurologia i Neurochirurgia Polska</i> , 2021 ,	1	2
140	The Phenomenon of Exquisite Motor Control in Tic Disorders and its Pathophysiological Implications. <i>Movement Disorders</i> , 2021 , 36, 1308-1315	7	3
139	Case in Context: Tourette Syndrome. <i>Cannabis and Cannabinoid Research</i> , 2021 , 6, 88-91	4.6	1
138	Challenges in the Diagnosis and Assessment in Patients with Tourette Syndrome and Comorbid Obsessive-Compulsive Disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2021 , 17, 1253-1266	3.1	3
137	Elevated Free Phosphatidylcholine Levels in Cerebrospinal Fluid Distinguish Bacterial from Viral CNS Infections. <i>Cells</i> , 2021 , 10,	7.9	3
136	Randomized double-blind sham-controlled trial of thalamic versus GPi stimulation in patients with severe medically refractory Gilles de la Tourette syndrome. <i>Brain Stimulation</i> , 2021 , 14, 662-675	5.1	5

135	Tourette-Syndrom: Wer tickt hier richtig?. <i>CME (Berlin, Germany)</i> , 2021 , 18, 51-58	0	
134	Is Tourette syndrome a rare disease?. <i>F1000Research</i> , 2021 , 10, 434	3.6	1
133	Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A 12-Week, Randomized, Controlled Study. <i>Movement Disorders</i> , 2021 , 36, 2413-2418	7	7
132	Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. <i>Journal of Cannabis Research</i> , 2021 , 3, 22	2.5	13
131	European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part II: psychological interventions. <i>European Child and Adolescent Psychiatry</i> , 2021 , 1	5.5	9
130	Developing the Premonitory Urges for Tic Disorders Scale-Revised (PUTS-R). <i>Journal of Neuropsychology</i> , 2021 , 15, 129-142	2.6	4
129	Two Decades of the International Association for Cannabinoid Medicines: 20 Years of Supporting Research and Activities Toward the Medicinal Use of Cannabis and Cannabinoids. <i>Cannabis and Cannabinoid Research</i> , 2021 , 6, 82-87	4.6	0
128	Synaptic processes and immune-related pathways implicated in Tourette syndrome. <i>Translational Psychiatry</i> , 2021 , 11, 56	8.6	11
127	Association of Group A Exposure and Exacerbations of Chronic Tic Disorders: A Multinational Prospective Cohort Study. <i>Neurology</i> , 2021 , 96, e1680-e1693	6.5	18
126	Potential impact of COVID-19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the CANNA-TICS study. <i>Pharmaceutical Statistics</i> , 2021 , 20, 675-691	1	0
125	European clinical guidelines for Tourette syndrome and other tic disorders: summary statement. <i>European Child and Adolescent Psychiatry</i> , 2021 , 1	5.5	10
124	Cannabis Improves Stuttering: Case Report and Interview with the Patient. <i>Cannabis and Cannabinoid Research</i> , 2021 , 6, 372-380	4.6	
123	Validation of the Rage Attack Questionnaire-Revised (RAQ-R) in a Mixed Psychiatric Population. <i>Frontiers in Psychiatry</i> , 2021 , 12, 724802	5	
122	Stop that! It's not Tourette's but a new type of mass sociogenic illness. <i>Brain</i> , 2021 ,	11.2	10
121	Intravenous Immunoglobulin Treatment Did Not Improve Tics in a Patient With Gilles de la Tourette Syndrome and Intrathecal Antibody Synthesis. <i>Frontiers in Neurology</i> , 2020 , 11, 110	4.1	2
120	Phosphatidylcholine PC ae C44:6 in cerebrospinal fluid is a sensitive biomarker for bacterial meningitis. <i>Journal of Translational Medicine</i> , 2020 , 18, 9	8.5	6
119	Neural correlates of performance monitoring in adult patients with Gilles de la Tourette syndrome: A study of event-related potentials. <i>Clinical Neurophysiology</i> , 2020 , 131, 597-608	4.3	4
118	The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders. <i>Frontiers in Psychiatry</i> , 2020 , 11, 575826	5	6

117	Cannabis Improves Obsessive-Compulsive Disorder-Case Report and Review of the Literature. <i>Frontiers in Psychiatry</i> , 2020 , 11, 681	5	5
116	Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome. <i>Neuropsychopharmacology</i> , 2020 , 45, 1323-1329	8.7	21
115	Antibodies to neuronal surface proteins in Tourette Syndrome: Lack of evidence in a European paediatric cohort. <i>Brain, Behavior, and Immunity</i> , 2019 , 81, 665-669	16.6	14
114	Tic disorders revisited: introduction of the term "tic spectrum disorders". <i>European Child and Adolescent Psychiatry</i> , 2019 , 28, 1129-1135	5.5	32
113	Serotonin transporter binding is increased in Tourette syndrome with Obsessive Compulsive Disorder. <i>Scientific Reports</i> , 2019 , 9, 972	4.9	12
112	Kynurenine Is a Cerebrospinal Fluid Biomarker for Bacterial and Viral Central Nervous System Infections. <i>Journal of Infectious Diseases</i> , 2019 , 220, 127-138	7	17
111	A peek into premonitory urges in Tourette syndrome: Temporal evolution of neurophysiological oscillatory signatures. <i>Parkinsonism and Related Disorders</i> , 2019 , 65, 153-158	3.6	7
110	Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. <i>Neurology</i> , 2019 , 92, 896-906	6.5	154
109	Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. <i>Neurology</i> , 2019 , 92, 907-915	6.5	91
108	Interrogating the Genetic Determinants of Tourette Syndrome and Other Tic Disorders Through Genome-Wide Association Studies. <i>American Journal of Psychiatry</i> , 2019 , 176, 217-227	11.9	95
107	The Rage Attack Questionnaire-Revised (RAQ-R): Assessing Rage Attacks in Adults With Tourette Syndrome. <i>Frontiers in Psychiatry</i> , 2019 , 10, 956	5	12
106	European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents. <i>European Child and Adolescent Psychiatry</i> , 2019 , 28, 91-109	5.5	25
105	Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome. <i>Medical Cannabis and Cannabinoids</i> , 2019 , 2, 60-63	4.1	4
104	Immunity in Gilles de la Tourette-Syndrome: Results From a Cerebrospinal Fluid Study. <i>Frontiers in Neurology</i> , 2019 , 10, 732	4.1	14
103	Possible Role of the Endocannabinoid System in Tourette Syndrome 2019 ,		3
102	Treatment of Gilles de la Tourette Syndrome with Cannabis-Based Medicine: Results from a Retrospective Analysis and Online Survey. <i>Cannabis and Cannabinoid Research</i> , 2019 , 4, 265-274	4.6	17
101	The spectrum of involuntary vocalizations in humans: A video atlas. <i>Movement Disorders</i> , 2019 , 34, 1774-1791		19
100	Position-Dependent Dysfunction of Deep Brain Stimulation in Tourette Syndrome: Diagnostic Clues. <i>Tremor and Other Hyperkinetic Movements</i> , 2019 , 9,	2	

99	Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders. <i>Depression and Anxiety</i> , 2019 , 36, 198-212	8.4	30
98	Cannabinoids in functional tic-like movements. <i>Parkinsonism and Related Disorders</i> , 2019 , 60, 179-181	3.6	2
97	Cannabis-basierte Medikamente: therapeutisches Potenzial und praktische Anwendung. <i>PSYCH Up2date</i> , 2018 , 12, 19-33	0.1	3
96	Investigation of previously implicated genetic variants in chronic tic disorders: a transmission disequilibrium test approach. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018 , 268, 301-316	5.1	15
95	Pallidal and thalamic neural oscillatory patterns in tourette syndrome. <i>Annals of Neurology</i> , 2018 , 84, 505-514	9.4	43
94	Intact automatic motor inhibition in patients with tourette syndrome. <i>Movement Disorders</i> , 2018 , 33, 1800-1804	7	9
93	De Novo Sequence and Copy Number Variants Are Strongly Associated with Tourette Disorder and Implicate Cell Polarity in Pathogenesis. <i>Cell Reports</i> , 2018 , 24, 3441-3454.e12	10.6	51
92	Gilles de la Tourette syndrome is associated with hypermethylation of the dopamine D2 receptor gene. <i>Journal of Psychiatric Research</i> , 2017 , 86, 1-8	5.2	24
91	The human globus pallidus internus is sensitive to rewards - Evidence from intracerebral recordings. <i>Brain Stimulation</i> , 2017 , 10, 657-663	5.1	9
90	Rare Copy Number Variants in NRXN1 and CNTN6 Increase Risk for Tourette Syndrome. <i>Neuron</i> , 2017 , 94, 1101-1111.e7	13.9	103
89	Pathological glutamatergic neurotransmission in Gilles de la Tourette syndrome. <i>Brain</i> , 2017 , 140, 218-234	14.2	43
88	Cognitive flexibility and its electrophysiological correlates in Gilles de la Tourette syndrome. <i>Developmental Cognitive Neuroscience</i> , 2017 , 27, 78-90	5.5	23
87	Speechlessness in Gilles de la Tourette Syndrome: Cannabis-Based Medicines Improve Severe Vocal Blocking Tics in Two Patients. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	18
86	Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols. <i>Brain Sciences</i> , 2017 , 7,	3.4	25
85	Association of AADAC Deletion and Gilles de la Tourette Syndrome in a Large European Cohort. <i>Biological Psychiatry</i> , 2016 , 79, 383-391	7.9	26
84	New Insights into Clinical Characteristics of Gilles de la Tourette Syndrome: Findings in 1032 Patients from a Single German Center. <i>Frontiers in Neuroscience</i> , 2016 , 10, 415	5.1	69
83	Aripiprazole Improves Associated Comorbid Conditions in Addition to Tics in Adult Patients with Gilles de la Tourette Syndrome. <i>Frontiers in Neuroscience</i> , 2016 , 10, 416	5.1	26
82	Effect of Deep Brain Stimulation on Regional Cerebral Blood Flow in Patients with Medically Refractory Tourette Syndrome. <i>Frontiers in Psychiatry</i> , 2016 , 7, 118	5	12

81	The ONLINE-TICS Study Protocol: A Randomized Observer-Blind Clinical Trial to Demonstrate the Efficacy and Safety of Internet-Delivered Behavioral Treatment for Adults with Chronic Tic Disorders. <i>Frontiers in Psychiatry</i> , 2016 , 7, 119	5	22
80	TS-EUROTRAIN: A European-Wide Investigation and Training Network on the Etiology and Pathophysiology of Gilles de la Tourette Syndrome. <i>Frontiers in Neuroscience</i> , 2016 , 10, 384	5.1	9
79	Increased beta rhythm as an indicator of inhibitory mechanisms in tourette syndrome. <i>Movement Disorders</i> , 2016 , 31, 384-92	7	12
78	Current and Future Needs and Applications for Cannabis. <i>Critical Reviews in Plant Sciences</i> , 2016 , 35, 425-426	5.6	6
77	Medicinal Uses of Marijuana and Cannabinoids. <i>Critical Reviews in Plant Sciences</i> , 2016 , 35, 378-405	5.6	33
76	"I swear it is TouretteQ!": On functional coprolalia and other tic-like vocalizations. <i>Psychiatry Research</i> , 2016 , 246, 821-826	9.9	32
75	Severe self-injurious behavior with teeth extraction in a boy with Tourette syndrome. <i>Pediatric Neurology</i> , 2015 , 52, e5	2.9	3
74	Patients with Gilles de la Tourette syndrome have widespread personality differences. <i>Psychiatry Research</i> , 2015 , 228, 765-73	9.9	16
73	Narcissistic vulnerability is a common cause for depression in patients with Gilles de la Tourette syndrome. <i>Psychiatry Research</i> , 2015 , 230, 695-703	9.9	7
72	Obsessive-compulsive disorder is a heterogeneous disorder: evidence from diffusion tensor imaging and magnetization transfer imaging. <i>BMC Psychiatry</i> , 2015 , 15, 135	4.2	19
71	Gilles de la Tourette syndrome is not linked to contactin-associated protein receptor 2 antibodies. <i>Molecular Brain</i> , 2015 , 8, 62	4.5	8
70	Cannabinoids and the Tourette syndrome 2015 , 227-245		1
69	Comparative characterization of single cell activity in the globus pallidus internus of patients with dystonia or Tourette syndrome. <i>Journal of Neural Transmission</i> , 2015 , 122, 687-99	4.3	30
68	Tourette patientsQnisbelief of a tic rebound is due to overall difficulties in reliable tic rating. <i>Journal of Psychosomatic Research</i> , 2014 , 76, 472-6	4.1	35
67	Costs of control: decreased motor cortex engagement during a Go/NoGo task in TouretteQ syndrome. <i>Brain</i> , 2014 , 137, 122-36	11.2	65
66	Can tics be performed convincingly by an actor?. <i>Behavioural Neurology</i> , 2014 , 2014, 893859	3	1
65	Altered intrahemispheric structural connectivity in Gilles de la Tourette syndrome. <i>NeuroImage: Clinical</i> , 2014 , 4, 174-81	5.3	48
64	Tics are caused by alterations in prefrontal areas, thalamus and putamen, while changes in the cingulate gyrus reflect secondary compensatory mechanisms. <i>BMC Neuroscience</i> , 2014 , 15, 6	3.2	43

63	The medicinal use of cannabis and cannabinoids--an international cross-sectional survey on administration forms. <i>Journal of Psychoactive Drugs</i> , 2013 , 45, 199-210	3.6	144
62	Surgical treatment of Tourette syndrome. <i>Neuroscience and Biobehavioral Reviews</i> , 2013 , 37, 1178-85	9	36
61	Impact of placebo assignment in clinical trials of tic disorders. <i>Movement Disorders</i> , 2013 , 28, 1288-92	7	29
60	Treatment of Tourette Syndrome with Cannabinoids. <i>Behavioural Neurology</i> , 2013 , 27, 119-124	3	58
59	Treatment of Tourette syndrome with cannabinoids. <i>Behavioural Neurology</i> , 2013 , 27, 119-24	3	23
58	Cannabis therapy. <i>Deutsches A&#x0308;rzteblatt International</i> , 2013 , 110, 144	2.5	1
57	In reply. <i>Deutsches A&#x0308;rzteblatt International</i> , 2013 , 110, 175	2.5	
56	Therapieresistente Patienten profitieren von THS. <i>Neurotransmitter</i> , 2013 , 24, 60-67	0.1	
55	Lateral frontal cortex volume reduction in Tourette syndrome revealed by VBM. <i>BMC Neuroscience</i> , 2012 , 13, 17	3.2	28
54	Monolingual coprolalia in bilingual patients with Tourette syndrome. <i>Movement Disorders</i> , 2012 , 27, 1468		2
53	Increased sensory feedback in Tourette syndrome. <i>NeuroImage</i> , 2012 , 63, 119-25	7.9	33
52	Tourette syndrome and other tic disorders in childhood, adolescence and adulthood. <i>Deutsches A&#x0308;rzteblatt International</i> , 2012 , 109, 821-288	2.5	33
51	Aripiprazole for the treatment of Tourette syndrome: a case series of 100 patients. <i>Journal of Clinical Psychopharmacology</i> , 2012 , 32, 548-50	1.7	30
50	The therapeutic potential of cannabis and cannabinoids. <i>Deutsches A&#x0308;rzteblatt International</i> , 2012 , 109, 495-501	2.5	176
49	Oligoclonal bands in cerebrospinal fluid in patients with Tourette syndrome. <i>Movement Disorders</i> , 2011 , 26, 343-6	7	17
48	European clinical guidelines for Tourette syndrome and other tic disorders. Part IV: deep brain stimulation. <i>European Child and Adolescent Psychiatry</i> , 2011 , 20, 209-17	5.5	119
47	Does Tourette syndrome prevent tardive dyskinesia?. <i>Movement Disorders</i> , 2011 , 26, 2442-3	7	32
46	Treatment of tics in patients with Tourette syndrome: recommendations according to the European Society for the Study of Tourette Syndrome. <i>Movement Disorders</i> , 2011 , 26, 2447; author reply 2448	7	16

45	Cost of illness in patients with Gilles de la Tourette syndrome. <i>Journal of Neurology</i> , 2010 , 257, 1055-61	5.5	17
44	Health-related quality of life in patients with Gilles de la Tourette syndrome. <i>Movement Disorders</i> , 2010 , 25, 309-14	7	73
43	Imitation in patients with Gilles de la Tourette syndrome--a behavioral study. <i>Movement Disorders</i> , 2010 , 25, 991-9	7	21
42	Is it a tic?--Twenty seconds to make a diagnosis. <i>Movement Disorders</i> , 2010 , 25, 1106-8	7	34
41	Interhemispheric motor networks are abnormal in patients with Gilles de la Tourette syndrome. <i>Movement Disorders</i> , 2010 , 25, 2828-37	7	38
40	Structural changes in the somatosensory system correlate with tic severity in Gilles de la Tourette syndrome. <i>Brain</i> , 2009 , 132, 765-77	11.2	123
39	Prefrontal and anterior cingulate cortex abnormalities in Tourette Syndrome: evidence from voxel-based morphometry and magnetization transfer imaging. <i>BMC Neuroscience</i> , 2009 , 10, 47	3.2	118
38	Coprophomina in Tourette syndrome. <i>Developmental Medicine and Child Neurology</i> , 2009 , 51, 218-27	3.3	104
37	Tourette syndrome. <i>Current Topics in Behavioral Neurosciences</i> , 2009 , 1, 397-410	3.4	3
36	Immunophenotyping in Tourette syndrome--a pilot study. <i>European Journal of Neurology</i> , 2008 , 15, 749-53	3.3	18
35	The influence of different food and drink on tics in Tourette syndrome. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2008 , 97, 442-6	3.1	22
34	Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. <i>Expert Review of Neurotherapeutics</i> , 2008 , 8, 1037-48	4.3	89
33	Role of the novel tryptophan hydroxylase-2 gene in Tourette syndrome. <i>Molecular Psychiatry</i> , 2007 , 12, 617-9	15.1	35
32	Chorea-acanthocytosis in monozygotic twins: clinical findings and neuropathological changes as detected by diffusion tensor imaging, FDG-PET and (123)I-beta-CIT-SPECT. <i>Journal of Neurology</i> , 2007 , 254, 1081-8	5.5	46
31	The Pathophysiological Role of the Serotonergic System in Tourette Syndrome. <i>Current Psychiatry Reviews</i> , 2007 , 3, 271-276	0.9	
30	Feasibility of central cannabinoid CB1 receptor imaging with [124I]AM281 PET demonstrated in a schizophrenic patient. <i>Psychiatry Research - Neuroimaging</i> , 2006 , 147, 249-56	2.9	17
29	Neuropsychologische Störungen bei einem monozygoten Zwillingsspaar mit Chorea-Akanthozytose. <i>Zeitschrift für Neuropsychologie = Journal of Neuropsychology</i> , 2006 , 17, 123-130	0.5	2
28	Serotonin transporter binding in Tourette Syndrome. <i>Neuroscience Letters</i> , 2005 , 385, 120-5	3.3	66

27	Tourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene 2004 , 127B, 97-103		30
26	[123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Delta9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients. <i>Biological Psychiatry</i> , 2004 , 55, 904-15	7.9	43
25	Cannabinoids reduce symptoms of Tourette syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2003 , 4, 1717-25	4	44
24	Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. <i>Neuropsychopharmacology</i> , 2003 , 28, 384-8	8.7	56
23	Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. <i>Journal of Clinical Psychiatry</i> , 2003 , 64, 459-65	4.6	155
22	Disturbed monitoring and response inhibition in patients with Gilles de la Tourette syndrome and co-morbid obsessive compulsive disorder. <i>Behavioural Neurology</i> , 2003 , 14, 29-37	3	52
21	Tourette syndrome and obsessive-compulsive disorder: event-related brain potentials show similar mechanisms [correction of mechanisms] of frontal inhibition but dissimilar target evaluation processes. <i>Behavioural Neurology</i> , 2003 , 14, 9-17	3	31
20	Excessive action monitoring in Tourette syndrome. <i>Journal of Neurology</i> , 2002 , 249, 961-6	5.5	68
19	Combined Treatment of Tourette Syndrome with Δ -9-THC and Dopamine Receptor Antagonists. <i>Journal of Cannabis Therapeutics</i> , 2002 , 2, 145-154		8
18	Treatment of Tourette syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. <i>Pharmacopsychiatry</i> , 2002 , 35, 57-61	2	162
17	The treatment of Tourette syndrome: current opinions. <i>Expert Opinion on Pharmacotherapy</i> , 2002 , 3, 899-914	4	20
16	Electrophysiological measures and dual-task performance in Tourette syndrome indicate deficient divided attention mechanisms. <i>European Journal of Neurology</i> , 2001 , 8, 253-60	6	31
15	Altered inhibition of motor responses in Tourette Syndrome and Obsessive-Compulsive Disorder. <i>Acta Neurologica Scandinavica</i> , 2001 , 104, 36-43	3.8	65
14	Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance. <i>Pharmacopsychiatry</i> , 2001 , 34, 19-24	2	35
13	Mitochondriopathy, blepharospasm, and treatment with botulinum toxin. <i>Muscle and Nerve</i> , 2000 , 23, 647-8	3.4	10
12	Dopamine D2 receptor imaging in Gilles de la Tourette syndrome. <i>Acta Neurologica Scandinavica</i> , 2000 , 101, 165-71	3.8	46
11	Dopamine transporter binding in Gilles de la Tourette syndrome. <i>Journal of Neurology</i> , 2000 , 247, 514-20	5.5	71
10	Cannabis in movement disorders. <i>Complementary Medicine Research</i> , 1999 , 6 Suppl 3, 23-7	1.3	43

9	Effects of fentanyl and low doses of alcohol on neuropsychological performance in healthy subjects. <i>Neuropsychobiology</i> , 1999 , 39, 38-43	4	18
8	Nabilone increases choreatic movements in Huntington's disease. <i>Movement Disorders</i> , 1999 , 14, 1038-40		54
7	Effects of acamprosate on memory in healthy young subjects. <i>Journal of Studies on Alcohol and Drugs</i> , 1999 , 60, 172-5		17
6	Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. <i>American Journal of Psychiatry</i> , 1999 , 156, 495	11.9	21
5	Cannabinoids: possible role in patho-physiology and therapy of Gilles de la Tourette syndrome. <i>Acta Psychiatrica Scandinavica</i> , 1998 , 98, 502-6	6.5	95
4	Gilles de la Tourette - Syndrom - Eine aktuelle Übersicht. <i>Aktuelle Neurologie</i> , 1997 , 24, 12-19		5
3	Alcohol withdrawal and Tourette's syndrome. <i>Neurology</i> , 1997 , 48, 1478-9	6.5	9
2	Event-related brain potentials show changed attentional mechanisms in Gilles de la Tourette Syndrome. <i>European Journal of Neurology</i> , 1997 , 4, 152-61	6	17
1	Is Tourette syndrome a rare condition?. <i>F1000Research</i> , 10, 434	3.6	1